Q3 2020 Sales Performance

Pharmaceuticals Q3 2020 Sales All figures £m Q3 2020 Total: £4, 192m: -3% CER; -7% AER +12% CER +8% AER -18% CER -23% AER gsk Operating margin +470bps CER +390bps AER (+ Sales New launches: Trelegy, Nucala, Dovato, Juluca, Zejula 28.0% (+ Sustained Benlysta growth 24.1% 2,486 2,308 2,223 1,706 806 978 1,175 1,093 1,267 1,216 Q319 Q320 Q319 Q320 Q319 Q320 Oncology Respiratory CEP HIV Impact of generics on Established products Pandemic-related lower demand for antibiotics Operating profit + Product mix + Favourable 2019 one-offs comparison + Tight control of costs Investment in new product support and targeted R&D 89

View entire presentation